Regulus Therapeutics Inc (NASDAQ:RGLS) Expected to Post Earnings of -$0.07 Per Share

Share on StockTwits

Equities research analysts expect that Regulus Therapeutics Inc (NASDAQ:RGLS) will announce earnings of ($0.07) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Regulus Therapeutics’ earnings, with the highest EPS estimate coming in at $0.11 and the lowest estimate coming in at ($0.24). Regulus Therapeutics posted earnings per share of ($0.98) during the same quarter last year, which suggests a positive year-over-year growth rate of 92.9%. The business is expected to announce its next quarterly earnings results on Monday, March 16th.

According to Zacks, analysts expect that Regulus Therapeutics will report full-year earnings of ($0.86) per share for the current year, with EPS estimates ranging from ($1.12) to ($0.59). For the next year, analysts forecast that the company will report earnings of ($0.87) per share, with EPS estimates ranging from ($1.03) to ($0.70). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Regulus Therapeutics.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.26). Regulus Therapeutics had a negative return on equity of 163,378.48% and a negative net margin of 325.85%. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million.

RGLS has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, August 13th. HC Wainwright initiated coverage on Regulus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $2.00 price objective on the stock. Wedbush reaffirmed a “hold” rating and issued a $1.00 price objective on shares of Regulus Therapeutics in a research note on Thursday, November 14th. Finally, Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research note on Wednesday, November 20th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $1.31.

Shares of NASDAQ RGLS traded down $0.04 during midday trading on Tuesday, hitting $0.74. The stock had a trading volume of 26,583 shares, compared to its average volume of 182,084. The company has a market capitalization of $15.50 million, a price-to-earnings ratio of -0.13 and a beta of 1.55. Regulus Therapeutics has a 1-year low of $0.50 and a 1-year high of $1.65. The company has a fifty day moving average price of $0.71 and a 200 day moving average price of $0.84.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CVI Holdings LLC acquired a new position in shares of Regulus Therapeutics in the 2nd quarter valued at about $568,000. Samsara BioCapital LLC acquired a new position in shares of Regulus Therapeutics in the 2nd quarter valued at about $1,131,000. EcoR1 Capital LLC acquired a new position in shares of Regulus Therapeutics in the 2nd quarter valued at about $1,389,000. Finally, NEA Management Company LLC lifted its stake in shares of Regulus Therapeutics by 124.1% in the 2nd quarter. NEA Management Company LLC now owns 2,052,455 shares of the biopharmaceutical company’s stock valued at $2,566,000 after purchasing an additional 1,136,704 shares in the last quarter. 36.84% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

See Also: Buy-Side Analysts

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.